Health Care [ 5/12 ] | Biotechnology [ 33/74 ]
NASDAQ | Common Stock
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency.
Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies.
The company was incorporated in 1988 and is based in Tarrytown, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 26 | 9.47 Increased by +15.21% | 9.16 Increased by +3.38% |
| Jan 30, 26 | 11.44 Decreased by -5.22% | 10.52 Increased by +8.75% |
| Oct 30, 25 | 11.83 Decreased by -5.06% | 9.67 Increased by +22.34% |
| Aug 1, 25 | 12.89 Increased by +11.51% | 8.44 Increased by +52.73% |
| Apr 29, 25 | 8.22 Decreased by -13.93% | 8.48 Decreased by -3.07% |
| Feb 4, 25 | 12.07 Increased by +1.77% | 11.19 Increased by +7.86% |
| Oct 31, 24 | 12.46 Increased by +7.51% | 11.70 Increased by +6.50% |
| Aug 1, 24 | 11.56 Increased by +12.89% | 10.61 Increased by +8.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 3.61 B Increased by +19.04% | 727.20 M Decreased by -10.08% | Increased by +20.17% Decreased by -24.46% |
| Dec 31, 25 | 3.88 B Increased by +2.51% | 844.60 M Decreased by -7.97% | Increased by +21.74% Decreased by -10.22% |
| Sep 30, 25 | 3.75 B Increased by +0.90% | 1.46 B Increased by +8.91% | Increased by +38.89% Increased by +7.93% |
| Jun 30, 25 | 3.68 B Increased by +3.62% | 1.39 B Decreased by -2.84% | Increased by +37.86% Decreased by -6.24% |
| Mar 31, 25 | 3.03 B Decreased by -3.70% | 808.70 M Increased by +12.01% | Increased by +26.70% Increased by +16.31% |
| Dec 31, 24 | 3.79 B Increased by +10.33% | 917.70 M Decreased by -20.86% | Increased by +24.22% Decreased by -28.27% |
| Sep 30, 24 | 3.72 B Increased by +10.65% | 1.34 B Increased by +33.02% | Increased by +36.03% Increased by +20.22% |
| Jun 30, 24 | 3.55 B Increased by +12.32% | 1.43 B Increased by +47.90% | Increased by +40.38% Increased by +31.68% |